Toggle light / dark theme

Sickle Cell Anemia Patient Becomes First Person in the U.S. to Have Her Genes Edited With CRISPR

Last week, a woman named Victoria Gray became the first person in the U.S. to have her cells edited with CRISPR. The 41-year-old patient was suffering from sickle cell anemia.

RELATED: FIRST HUMAN TRIAL USING CRISPR GENE-EDITING IN US BEGINS

The condition, caused by a genetic mutation that messes with the shape of red blood cells, causes havoc on patients, and to make things even worse, the options for treatment are very limited and ineffective. The only current treatment for sickle cell anemia patients is a donor transplant that works for just 10% of patients, but all that is about to change.

Dr Aubrey de Grey | Investing in the Age of Longevity 2019

Rejuvenation Biotechnology: on track to be the biggest industry ever.

Dr Aubrey de Grey, CSO at the SENS Research Foundation speaking at Master Investor’s Investing in the Age of Longevity 2019 event. Aubrey discusses Rejuvenation biotechnology and how it’s on track to become the biggest industry ever.

Master Investor is an investment media and events company that delivers independent, financial commentary and analysis to UK private investors and traders through events, magazines, news, blogs, podcasts and daily/weekly newsletters.
Read our latest magazine at www.masterinvestor.co.uk/magazine
Book a free ticket (use code MIYT) to attend the annual Master Investor Show (28th March 2020): https://masterinvestorshow-2020.reg.buzz
Keep in touch:
Newsletter | https://masterinvestor.co.uk/subscribe
Twitter | https://twitter.com/masterinvestor
Facebook | https://facebook.com/masterinvestor
LinkedIn | https://www.linkedin.com/company/masterinvestor

Reason | Investing in the Age of Longevity 2019

Gene therapies to reverse immunosenescence and atherosclerosis.

CEO of Repair Biotechnologies speaking at Master Investor’s Investing in the Age of Longevity 2019 event. Reason discusses gene therapies to reverse immunosenescence and atherosclerosis.

Master Investor is an investment media and events company that delivers independent, financial commentary and analysis to UK private investors and traders through events, magazines, news, blogs, podcasts and daily/weekly newsletters.

Read our latest magazine at www.masterinvestor.co.uk/magazine

Book a free ticket (use code MIYT) to attend the annual Master Investor Show (28th March 2020): https://masterinvestorshow-2020.reg.buzz

Keep in touch:

Internal brain timers linked with motivation and behavior

Time can be measured in many ways: a watch, a sundial, or the body’s natural circadian rhythms. But what about the sexual behavior of a fruit fly?

“If you ask a bunch of scientists whether animals can keep time, many would say they cannot, that things happen over time—but time itself is not measured,” says Michael Crickmore, Ph.D., a researcher in Boston Children’s Hospital’s F.M. Kirby Neurobiology Center whose laboratory studies motivation. But in new research published in the journal Neuron in collaboration with the lab of Dragana Rogulja, Ph.D. at Harvard Medical School, he shows that the mating of fruit flies is not haphazard. Instead, motivation and behavior are under the control of that track time.

Crickmore uses the mating drive in to study how motivations are produced by the brain.

Antivirals for the Gut? Study Points To Potential New Gut (and Brain) Treatment

A Gulf War Illness study finds a connection between dysregulated gut flora, leaky gut and neuroinflammation – and a new way to potentially resolve it.

It’s nice when the government has your back. After years of neglect, the federal government finally appears, at least regarding medical research, to have Gulf War Illness (GWI) veterans’ backs.

Epigenetic Aging: Can It Be Slowed With Diet?

New post!


Having a faster rate of epigenetic aging, as measured by the epigenetic age metric, AgeAccelGrim, is associated with a significantly increased risk of death for all causes in a variety of cohorts, including the Framingham Heart Study (FHS), the Women’s Health Initiative (WHI) study, the InChianti study, the Jackson Heart Study (JHS), and collectively, when evaluated as a meta-analysis (Lu et al. 2019):

Screen Shot 2019-12-07 at 2.23.27 PM.png

With the goal of minimizing disease risk and maximizing longevity, can epigenetic aging be slowed? Shown below is the correlation between dietary components with AgeAccelGrim. Dietary factors that were significantly associated (the column labelled, “p”) with a younger epigenetic age were carbohydrate intake, dairy, whole grains, fruit, and vegetables. In contrast, dietary fat intake and red meat were associated with older epigenetic ages (Lu et al. 2019):

Families with long, healthy life spans focus of $68 million grant

Families with long, healthy life spans focus of $68 million grant~ via Washington University School of Medicine in St. Louis https://medicine.wustl.edu/news/families-with-long-healthy-l…ion-grant/


A few hundred of the thousands of proteins circulating in our blood turn out to be a fairly accurate forecaster of a person’s age, scientists reported Thursday — though one’s biological age, which doesn’t always match one’s number of years.

This “proteomic clock,” as the researchers call it, relies on measurements of levels of the proteins, which rise and fall over the years. While it’s a nifty discovery, for now it remains just that. Researchers need to first develop a much better understanding of these proteins; if they can, they said, it might be possible to one day look at their levels to gauge the success of drugs being tested in clinical trials, or even to develop a therapy from a cocktail of proteins that could act like a rejuvenation boost or improve health.

“Why are these proteins so tightly linked to aging?” said Tony Wyss-Coray, professor of neurology and neurological sciences at Stanford and the senior author of the paper4, which was published Thursday in the journal Nature Medicine.

Scientists develop a ‘clock’ to measure biological age based on blood

A few hundred of the thousands of proteins circulating in our blood turn out to be a fairly accurate forecaster of a person’s age, scientists reported Thursday — though one’s biological age, which doesn’t always match one’s number of years.

This “proteomic clock,” as the researchers call it, relies on measurements of levels of the proteins, which rise and fall over the years. While it’s a nifty discovery, for now it remains just that. Researchers need to first develop a much better understanding of these proteins; if they can, they said, it might be possible to one day look at their levels to gauge the success of drugs being tested in clinical trials, or even to develop a therapy from a cocktail of proteins that could act like a rejuvenation boost or improve health.

“Why are these proteins so tightly linked to aging?” said Tony Wyss-Coray, professor of neurology and neurological sciences at Stanford and the senior author of the paper4, which was published Thursday in the journal Nature Medicine.

Burzynski: Cancer Is Serious Business | Full Documentary | CANCER CURE

More: https://www.burzynskimovie.com/
About the director: https://ericmerola.com
A 2016 updated version of this story: http://estore.burzynskimovie.com/

More info http://www.burzynskimovie.com

Directed by Eric Merola
http://www.ericmerola.com

Learn more about the director: http://merolaproductions.com/eric-merola-bio

Burzynski, the Movie is an internationally award-winning documentary originally released in 2010 (with an Extended Edition released in 2011) that tells the true story of a medical doctor and Ph.D biochemist named Dr. Stanislaw Burzynski who won the largest, and possibly the most convoluted and intriguing legal battle against the Food & Drug Administration in American history.

His victorious battles with the United States government were centered around Dr. Burzynski’s gene-targeted cancer medicines he discovered in the 1970’s called Antineoplastons, which have currently completed Phase II FDA-supervised clinical trials in 2009 and has been given permission by the FDA to begin the final phase of FDA testing–randomized controlled clinical trials.